Production (Stage)
E
XORTX Therapeutics Inc. XRTX.V
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

03/31/2025 12/31/2024 09/30/2024 06/30/2024 03/31/2024
Net Income 70.31% -53.53% 90.09% 79.69% 51.15%
Total Depreciation and Amortization 5.71% -16.18% -16.32% -26.13% -13.44%
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items -83.76% 83.04% -365.73% -106.52% 41.09%
Change in Net Operating Assets 216.04% 111.33% 97.30% 239.78% -249.00%
Cash from Operations 44.12% 44.12% 54.03% 49.87% 39.61%
Capital Expenditure -- -- 100.00% 100.00% 92.83%
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities -43.84% 7.60% -2.29% 30.60% 31.85%
Cash from Investing -35.96% 15.98% 16.14% 43.20% 53.50%
Total Debt Issued -- -- -- -- --
Total Debt Repaid -16.52% -5.29% -25.00% -25.27% -80.82%
Issuance of Common Stock -20.01% 1,172,266.67% -59.66% -59.66% -59.66%
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities 33.00% -126.18% -431.23% -119.92% -112.73%
Cash from Financing -16.20% 869.73% -73.47% -70.84% -70.89%
Foreign Exchange rate Adjustments -300.00% -978.05% -71.43% 84.57% 96.51%
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash 52.36% 86.06% 27.20% 27.40% 9.56%